FGF21 and metabolic dysfunction-associated steatotic liver disease: Clinical evidence has indicated that FGF21 serum concentrations are elevated in MASLD patients and are positively correlated with intrahepatic TG levels, which suggests that FGF21 may be a biomarker for MASLD and may serve as a key regulator of lipid metabolism in the liver [187–189].